Analysts' consensus shows Axonics performing as expected, with no major estimate changes post recent results. Despite a predicted slowdown in revenue growth, Axonics is still expected to outpace the wider industry.
Axonics' consistent revenue growth, despite last year's lack of profit, has led to a 33% annual increase in share price over the past five years, making it a potential investment opportunity.
Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.
Investors believe in Axonics' potential for future revenue growth, supporting higher stock prices despite a high P/S ratio. They discount the chance of a revenue decrease, but risks and other factors must also be considered.
Axonics' strong revenue growth may be driving its stock performance and could be attractive for growth investors. The recent sell-off may open up investment opportunities if long-term growth signs are positive.
Upgrades •$Banc of California(BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22 •$庫倫佛寺銀行(CFR.US)$: Raymond James Upgrades to Outperform from Market Perform •$美國固安捷(GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform •$Invitation Homes(INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44) •$PCB Bancorp(PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...
Gainers -$聯合通訊(CNSL.US)$+14.6%: Searchlight affirms 34.6% active holding; to evaluate the possibility of a further investment in or full acquisition. -$Voyager Therapeutics(VYGR.US)$+12.2%: agrees to licensing option with$諾華製藥(NVS.US)$; Voyager receives $54 million upfront. -$荷蘭全球保險(AEG.US)$+6%: provides update on Russian and Belarusian investments following invasion of Ukraine. -$AZZ Inc(AZZ.US)$+...
Axonics股票討論區
• $博思艾倫諮詢公司(BAH.US)$: Goldman Sachs Upgrades to Buy from Neutral - PT $102 (from $83)
• $哈門那(HUM.US)$: UBS Upgrades to Buy from Neutral - PT $520 (from $486)
• $JB亨特運輸服務(JBHT.US)$: Deutsche Bank Upgrades to Buy from Hold - PT $230 (from $210)
Downgrades
• $JB亨特運輸服務(JBHT.US)$: B.Riley Downgrades to Neutral from Buy - PT $33 (from $62)
• $CACI國際(CACI.US)$: Goldman Sachs Downgrad...
• $Banc of California(BANC.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $庫倫佛寺銀行(CFR.US)$: Raymond James Upgrades to Outperform from Market Perform
• $美國固安捷(GWW.US)$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes(INVH.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US)$: Raymond James Upgrades to Outperform from Market Perfor...
- $聯合通訊(CNSL.US)$ +14.6%: Searchlight affirms 34.6% active holding; to evaluate the possibility of a further investment in or full acquisition.
- $Voyager Therapeutics(VYGR.US)$ +12.2%: agrees to licensing option with $諾華製藥(NVS.US)$; Voyager receives $54 million upfront.
- $荷蘭全球保險(AEG.US)$ +6%: provides update on Russian and Belarusian investments following invasion of Ukraine.
- $AZZ Inc(AZZ.US)$ +...
暫無評論